Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. - Wikidata - awgldk - TriplyDB

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.

http://www.wikidata.org/entity/Q35320304

about

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.MiR-21: an environmental driver of malignant melanoma?MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.Targeting mutant NRAS signaling pathways in melanoma.Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis.

P2860

Q30277902-1CF71410-956B-4071-93AB-517CB4A861DE Q33887664-796A669E-16C5-4C09-82A7-3370B01C56B6 Q35164121-E0F6C91F-3C91-4F32-BD30-B74F3E489020 Q35786021-F7646C7D-E9BD-4ACB-B023-0851D0E1B707 Q36682132-9D1AB6B8-3CC5-42CE-B40B-1FCBCCEBB645 Q36902066-41245402-B89E-4690-A8F8-8CEAA4F36738 Q38894416-06851893-7B8E-420D-ACBE-F029B04DE11B

P2860

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.

http://www.wikidata.org/entity/Q35320304

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@ast

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@en

type

label

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@ast

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@en

prefLabel

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@ast

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@en

P1433

Q35320304-7C9E3F6D-05EF-4266-9A13-CE1A3BC1FA33

P1476

Q35320304-3361435A-D660-4693-942B-7E4D44050206

P2093

Q35320304-15BA848A-0945-426D-A77A-B40B0C1D0242

Q35320304-5F7B8741-DAEB-43D0-8D8F-6B0A7BE10675

Q35320304-7D677C7B-944D-44A9-AFF2-4F3ED0C36E63

Q35320304-89AA5384-B223-4284-B797-4ED4F158888D

Q35320304-E5E60E42-18C6-4396-9AFA-3A0B07046426

P2860

Q35320304-00DA2118-361F-40D6-8C54-C50BBF0ED0CB

Q35320304-077DD149-BAD4-4D3C-9952-4C62FF0A1F0E

Q35320304-081E7C1E-0B3A-4259-854A-98D132215596

Q35320304-0829A49C-B9CF-425E-BE34-37B58EC600F4

Q35320304-0CC14AAF-872E-4A38-A4A2-ABFBAF6388EF

Q35320304-0EAFCC5D-15AA-480F-B7C1-624B36179BCC

Q35320304-1923AEE0-A0DD-42E3-B112-4FA8766C3822

Q35320304-1EBDFB96-F6C4-4C1D-9390-788AF3703FB3

Q35320304-1FD39DE3-8F72-4DC4-B630-CDC9851359D6

Q35320304-2205EFC6-2CCC-4CF2-94DA-8B8FE90B36A8

P304

Q35320304-50C1CC6F-4137-4585-B2BC-033C915A53C7

P31

Q35320304-4D250359-B288-4C63-8E06-8BD8C52A1BE0

P356

Q35320304-747DFC28-8AA1-464D-BF5D-DA0A0FD8B730

P433

Q35320304-BD6D4743-8172-4172-877E-4A03DC6B9993

P478

Q35320304-E208C130-AD5A-47D0-9C9D-850A3B6C5FC3

P50

Q35320304-219FC1D7-1ABD-44F2-BDF8-2477AE9C4FCD

P577

Q35320304-C4A1501E-5C5A-4F02-B1D7-D747E99B3A04

P698

Q35320304-7FD48BBA-CF83-4137-9E26-26F957400838

P932

Q35320304-46DD6AFB-6DDE-4B7E-AEB6-2EDB8ED41B5F

P356

P1433

P1476

Phosphoproteomic analysis of b ...... BRAF and NRAS mutant melanoma.

@en

P2093

Ana Cecelia Munko

http://www.w3.org/2001/XMLSchema#string

Bin Fang

http://www.w3.org/2001/XMLSchema#string

Geoffrey T Gibney

http://www.w3.org/2001/XMLSchema#string

Inna V Fedorenko

http://www.w3.org/2001/XMLSchema#string

John M Koomen

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

A landscape of driver mutations in melanoma

Melanoma genome sequencing reveals frequent PREX2 mutations

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Mutations of the BRAF gene in human cancer

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

P304

327-339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PMIC.201400200

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Keiran S M Smalley

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25339196

http://www.w3.org/2001/XMLSchema#string

P932

4389901

http://www.w3.org/2001/XMLSchema#string